Guillermo Ruiz-Irastorza

Summary

Affiliation: Hospital de Cruces
Country: Spain

Publications

  1. doi [The antiphospholipid syndrome in the 21st century]
    Guillermo Ruiz-Irastorza
    Hospital de Cruces, Barakaldo, Bizkaia, Espana
    Med Clin (Barc) 133:390-6. 2009
  2. doi Changes in vitamin D levels in patients with systemic lupus erythematosus: Effects on fatigue, disease activity, and damage
    Guillermo Ruiz-Irastorza
    Hospital de Cruces, Barakaldo, Spain
    Arthritis Care Res (Hoboken) 62:1160-5. 2010
  3. ncbi High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus
    Guillermo Ruiz-Irastorza
    Servicio de Medicina Interna, Hospital de Cruces, Universidad del Pais Vasco Euskal Herriko Unibertsitatea, Bizkaia, Spain
    Arch Intern Med 164:77-82. 2004
  4. doi Antiphospholipid syndrome
    Guillermo Ruiz-Irastorza
    Service of Internal Medicine, Hospital de Cruces University of the Basque Country, Bizkaia, Spain
    Lancet 376:1498-509. 2010
  5. pmc Predictors of major infections in systemic lupus erythematosus
    Guillermo Ruiz-Irastorza
    Department of Internal Medicine, Hospital de Cruces, University of the Basque Country, Pza Cruces s n, Barakaldo, Bizkaia, Spain
    Arthritis Res Ther 11:R109. 2009
  6. doi Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review
    G Ruiz-Irastorza
    Servicio de Medicina Interna, Hospital de Cruces, University of the Basque Country, 48903 Bizkaia, Spain
    Ann Rheum Dis 69:20-8. 2010
  7. doi Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences
    G Ruiz-Irastorza
    Servicio de Medicina Interna, Hospital de Cruces, 48903 Bizkaia, Spain
    Rheumatology (Oxford) 47:920-3. 2008
  8. ncbi A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies
    Guillermo Ruiz-Irastorza
    Hospital de Cruces, and University of the Basque Country, Bizkaia, Spain
    Arthritis Rheum 57:1487-95. 2007
  9. ncbi Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus
    G Ruiz-Irastorza
    Service and Department of Internal Medicine, Hospital de Cruces, Universidad del Pais Vasco Euskal Herriko Unibertsitatea, Bizkaia, The Basque Country, Spain
    Lupus 13:900-5. 2004
  10. ncbi Stroke and antiphospholipid syndrome: the treatment debate
    G Ruiz-Irastorza
    Servicio de Medicina Interna, Hospital de Cruces, 48903 Bizkaia, Spain
    Rheumatology (Oxford) 44:971-4. 2005

Collaborators

  • Munther A Khamashta
  • Mary Carmen Amigo
  • Gerard Espinosa
  • Beverley J Hunt
  • José Gabriel Erdozain
  • Ioana Ruiz-Arruza
  • Eguzkine Ochoa
  • Alvaro Danza
  • Iñigo Les
  • Irama Villar
  • Agustin Martinez-Berriotxoa
  • Amaia Ugarte
  • Miguel Angel Moran
  • Iván Cabezas-Rodríguez
  • Javier Nieto
  • Jose Alejandro Medina
  • Mikel Iriondo
  • Ana Bielsa
  • Ana M Zubiaga
  • Andone Estonba
  • Ignacio Pérez-Valero
  • Jose Luis Pomar
  • Oier Ateka-Barrutia
  • Maria Isabel Segura
  • Maria Victoria Egurbide
  • Ciriaco Aguirre
  • Jose Gabriel Erdozain
  • Maider Garmendia

Detail Information

Publications28

  1. doi [The antiphospholipid syndrome in the 21st century]
    Guillermo Ruiz-Irastorza
    Hospital de Cruces, Barakaldo, Bizkaia, Espana
    Med Clin (Barc) 133:390-6. 2009
    ..Low dose aspirin should be given to every pregnant woman with antiphospholipid antibodies, with the addition of low molecular weight heparin in those with previous thrombosis, previous fetal death or failure of monotherapy with aspirin...
  2. doi Changes in vitamin D levels in patients with systemic lupus erythematosus: Effects on fatigue, disease activity, and damage
    Guillermo Ruiz-Irastorza
    Hospital de Cruces, Barakaldo, Spain
    Arthritis Care Res (Hoboken) 62:1160-5. 2010
    ..To analyze whether changes in serum 25-hydroxyvitamin D (25[OH]D) levels affect activity, irreversible organ damage, and fatigue in systemic lupus erythematosus (SLE)...
  3. ncbi High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus
    Guillermo Ruiz-Irastorza
    Servicio de Medicina Interna, Hospital de Cruces, Universidad del Pais Vasco Euskal Herriko Unibertsitatea, Bizkaia, Spain
    Arch Intern Med 164:77-82. 2004
    ..Whether antiphospholipid syndrome (APS) is the cause of increased irreversible organ damage and mortality in lupus patients is not well established...
  4. doi Antiphospholipid syndrome
    Guillermo Ruiz-Irastorza
    Service of Internal Medicine, Hospital de Cruces University of the Basque Country, Bizkaia, Spain
    Lancet 376:1498-509. 2010
    ..Hydroxychloroquine is a potential additional treatment for this syndrome. Possible future therapies for non-pregnant patients with antiphospholipid syndrome are statins, rituximab, and new anticoagulant drugs...
  5. pmc Predictors of major infections in systemic lupus erythematosus
    Guillermo Ruiz-Irastorza
    Department of Internal Medicine, Hospital de Cruces, University of the Basque Country, Pza Cruces s n, Barakaldo, Bizkaia, Spain
    Arthritis Res Ther 11:R109. 2009
    ..Infections commonly complicate the course of systemic lupus erythematosus (SLE). Our aim is to investigate the clinical predictors of major infections in patients with SLE...
  6. doi Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review
    G Ruiz-Irastorza
    Servicio de Medicina Interna, Hospital de Cruces, University of the Basque Country, 48903 Bizkaia, Spain
    Ann Rheum Dis 69:20-8. 2010
    ..The aim of the present work was to analyse all the published evidence of the beneficial and adverse effects of AM therapy in systemic lupus erythematosus (SLE)...
  7. doi Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences
    G Ruiz-Irastorza
    Servicio de Medicina Interna, Hospital de Cruces, 48903 Bizkaia, Spain
    Rheumatology (Oxford) 47:920-3. 2008
    ..We aimed to establish the prevalence, predictors and clinical consequences of vitamin D deficiency in patients with SLE...
  8. ncbi A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies
    Guillermo Ruiz-Irastorza
    Hospital de Cruces, and University of the Basque Country, Bizkaia, Spain
    Arthritis Rheum 57:1487-95. 2007
    ..To systematically review the efficacy and safety data of different therapeutic approaches in patients with antiphospholipid antibodies (aPL) and thrombosis...
  9. ncbi Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus
    G Ruiz-Irastorza
    Service and Department of Internal Medicine, Hospital de Cruces, Universidad del Pais Vasco Euskal Herriko Unibertsitatea, Bizkaia, The Basque Country, Spain
    Lupus 13:900-5. 2004
    ..11-10.03) and increasing damage since diagnosis (OR 2.46, 95% CI 1.24-4.87). No autoantibody was a predictor of the outcome 'SDI > or = 1 or death at five years'. The conclusion was that aPL predict early damage in patients with SLE...
  10. ncbi Stroke and antiphospholipid syndrome: the treatment debate
    G Ruiz-Irastorza
    Servicio de Medicina Interna, Hospital de Cruces, 48903 Bizkaia, Spain
    Rheumatology (Oxford) 44:971-4. 2005
    ..Due to the often devastating consequences of stroke, we believe there is a place for prolonged, high-intensity anticoagulation in patients with APS and cerebral arterial thrombosis...
  11. pmc Antimalarials may influence the risk of malignancy in systemic lupus erythematosus
    G Ruiz-Irastorza
    Servicio de Medicina Interna, Hospital de Cruces, 48903 Bizkaia, Spain
    Ann Rheum Dis 66:815-7. 2007
    ..Recent studies suggest that antimalarials have antineoplastic properties...
  12. ncbi Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus
    G Ruiz-Irastorza
    Department of Internal Medicine, Hospital de Cruces, University of the Basque Country, Bizkaia, Spain
    Lupus 15:577-83. 2006
    ..14 (95% CI 0.04-0.48). Our study shows a protective effect of antimalarials against thrombosis and an increased survival of SLE patients taking these drugs. These data support the routine use of antimalarials in all patients with SLE...
  13. ncbi Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus
    Agustin Martinez-Berriotxoa
    Service of Internal Medicine, Hospital de Cruces, Universidad del Pais Vasco Euskal Herriko Unibertsitatea, Bizkaia, The Basque Country, Spain
    Lupus 16:810-6. 2007
    ..Risk of thrombosis is not increased in SLE patients with negative LA and transiently positive aCL, even fulfilling Sapporo laboratory criteria, when compared with aPL-negative SLE patients...
  14. doi Lupus and pregnancy: integrating clues from the bench and bedside
    Guillermo Ruiz-Irastorza
    Department of Internal Medicine, Hospital de Cruces, University of the Basque Country, Bizkaia, Spain
    Eur J Clin Invest 41:672-8. 2011
    ..Postpartum follow-up is important...
  15. doi Prednisone in lupus nephritis: how much is enough?
    Guillermo Ruiz-Irastorza
    Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, Spain University of the Basque Country, Bizkaia, The Basque Country, Spain Electronic address
    Autoimmun Rev 13:206-14. 2014
    ..To assess the effectiveness and safety of a protocol using medium doses of prednisone to treat lupus nephritis...
  16. ncbi Antiphospholipid syndrome in pregnancy
    Guillermo Ruiz-Irastorza
    Department of Internal Medicine, Hospital de Cruces, University of the Basque Country, 48903 Bizkaia, Spain
    Rheum Dis Clin North Am 33:287-97, vi. 2007
    ..Doppler studies of the umbilical and uterine arteries play an important role in predicting APS-related complications during pregnancy...
  17. doi Intensity and duration of anticoagulation therapy in antiphospholipid syndrome
    Iñigo Les
    Autoimmune Diseases Research Unit, Service of Internal Medicine, Hospital Universitario Cruces, Bizkaia, Spain
    Semin Thromb Hemost 38:339-47. 2012
    ..Nevertheless, anticoagulation regimes of shorter duration could be given in selected patients with venous thromboembolism who have transient risk factors and a low-risk profile...
  18. doi Managing lupus patients during pregnancy
    Guillermo Ruiz-Irastorza
    Service and Department of Internal Medicine, Hospital de Cruces, University of the Basque Country, Bizkaia, Spain
    Best Pract Res Clin Rheumatol 23:575-82. 2009
    ..Post-partum follow-up is also essential...
  19. ncbi The treatment of antiphospholipid syndrome: a harmonic contrast
    Guillermo Ruiz-Irastorza
    Department of Internal Medicine, Hospital de Cruces, University of the Basque Country, 48903 Barakaldo, Bizkaia, Spain
    Best Pract Res Clin Rheumatol 21:1079-92. 2007
    ..Correction of vascular risk factors and a high-risk management of pregnancy, including Doppler studies of the uterine and umbilical vessels, are warranted. Hydroxychloroquine and statins are likely to become important in the future...
  20. doi Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy
    Guillermo Ruiz-Irastorza
    Autoimmune Diseases Research Unit, Department of Internal Medicine, Hospital Universitario Cruces, University of the Basque Country, UPV EHU, Bizkaia, Spain
    Autoimmun Rev 12:410-5. 2013
    ..To investigate the prevalence and predictors of pulmonary hypertension (PH) in patients with systemic lupus erythematosus (SLE) and to validate a diagnostic strategy...
  21. doi Glucocorticoid use and abuse in SLE
    Guillermo Ruiz-Irastorza
    Servicio de Medicina Interna Hospital de Cruces, 48903 Bizkaia, Spain
    Rheumatology (Oxford) 51:1145-53. 2012
    ..5 mg of prednisone seem to minimize adverse effects. Combination therapy with HCQ and the judicious use of immunosuppressive drugs help to keep prednisone therapy within those limits...
  22. ncbi Management of thrombosis in antiphospholipid syndrome and systemic lupus erythematosus in pregnancy
    Guillermo Ruiz-Irastorza
    Service and Department of Internal Medicine, Hospital de Cruces, University of the Basque Country, Bizkaia, Spain
    Ann N Y Acad Sci 1051:606-12. 2005
    ..Peripartum thromboprophylaxis with LMWH in women receiving aspirin-only regimens and prevention of osteoporosis in those treated with heparin are considered essential in the medical management of these patients...
  23. doi Peripheral arterial disease in systemic lupus erythematosus: prevalence and risk factors
    José Gabriel Erdozain
    From the Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Bizkaia Department of Internal Medicine, Hospital de Mendaro, Gipuzkoa, The Basque Country, Spain
    J Rheumatol 41:310-7. 2014
    ..To analyze the prevalence of peripheral arterial disease (PAD) and cardiovascular (CV) risk factors in a cohort of patients with systemic lupus erythematosus (SLE) and to identify variables potentially related to PAD...
  24. ncbi [Treatment of systemic lupus erythematosus: myths, certainties and doubts]
    Guillermo Ruiz-Irastorza
    Unidad de Investigación de Enfermedades Autoinmunes, Servicio de Medicina Interna, Hospital Universitario Cruces, Universidad del Pais Vasco Euskal Herriko Unibertsitatea, Barakaldo, Bizkaia, España Electronic address
    Med Clin (Barc) 141:533-42. 2013
    ..Hydroxichloroquine improves survival, decreases the risk of thrombosis and flares and is safe in pregnancy, and should be considered the baseline therapy in most SLE patients. ..
  25. doi Cardiac valve replacement in patients with antiphospholipid syndrome
    José Gabriel Erdozain
    Hospital Universitario Cruces, Barakaldo, Spain
    Arthritis Care Res (Hoboken) 64:1256-60. 2012
    ..To analyze the results of cardiac valve replacement in a multicenter cohort of patients with antiphospholipid syndrome (APS) and to identify prognostic factors of poor outcome...
  26. ncbi Antiphospohlipid syndrome in obstetrics
    Alvaro Danza
    Autoimmune Diseases Research Unit, Department of Internal Medicine, Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain
    Best Pract Res Clin Obstet Gynaecol 26:65-76. 2012
    ..Close blood pressure control and early detection of proteinuria, together with Doppler studies of the utero-placental circulation should be included in the management protocol...
  27. ncbi Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus
    Ioana Ruiz-Arruza
    Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Bizkaia, The Basque Country, Spain
    Rheumatology (Oxford) 53:1470-6. 2014
    ..The aim of this study was to analyse the relationship between glucocorticoids and damage accrual in SLE...
  28. pmc Thrombotic antiphospholipid syndrome shows strong haplotypic association with SH2B3-ATXN2 locus
    Eguzkine Ochoa
    Department of Genetics, Physical Anthropology and Animal Physiology School of Science and Technology, University of the Basque Country, UPV EHU, Leioa, Spain
    PLoS ONE 8:e67897. 2013
    ..Little is known about the genetic risk factors involved in thrombosis development among aPLA carriers...